Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI:10.2217/mmt-2016-0004

Adam C Olson, Samantha Thomas, Rosie Qin, Bhavana Singh, Joseph K Salama, John Kirkpatrick, April Ks Salama

{"title":"Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab.","authors":"Adam C Olson, Samantha Thomas, Rosie Qin, Bhavana Singh, Joseph K Salama, John Kirkpatrick, April Ks Salama","doi":"10.2217/mmt-2016-0004","DOIUrl":null,"url":null,"abstract":"Purpose: Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety.Methods: Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival.Results: We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis.Conclusion: SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"177-186"},"PeriodicalIF":1.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0004","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2016-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/8/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 10

Abstract

Purpose: Patients with melanoma treated with ipilimumab and radiosurgery (stereotactic radiosurgery [SRS]) were reviewed for efficacy/safety.

Methods: Patients who received ipilimumab and SRS for brain metastases were analyzed for control of SRS-treated metastasis and overall survival.

Results: We identified 27 patients, 26 were assessable for outcomes. Median time-to-treated metastasis progression was 6.3 months (95% CI: 3.1-12.2). Overall survival was 23.4 months (95% CI: 5.7-not estimable) for SRS prior to/during ipilimumab (n = 14), and 10.4 months (95% CI: 1.9-not estimable) for SRS after ipilimumab (n = 12). Overall, no unexpected toxicities were seen: 11% of patients experienced grade 3 CNS toxicity and 7% developed radionecrosis.

Conclusion: SRS for melanoma brain metastases with ipilimumab was well-tolerated. There may be improved survival for patients receiving SRS prior to/during ipilimumab.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

立体定向放射治疗接受伊匹单抗的黑色素瘤脑转移患者的预后和毒性。

目的:对伊匹单抗和放射手术(立体定向放射手术[SRS])治疗的黑色素瘤患者进行疗效/安全性评价。方法:对接受易普利姆单抗和SRS治疗脑转移的患者进行分析，以控制SRS治疗的转移和总生存期。结果:我们确定了27例患者，其中26例可评估预后。转移进展的中位治疗时间为6.3个月(95% CI: 3.1-12.2)。伊匹单抗治疗前/期间(n = 14)的SRS总生存期为23.4个月(95% CI: 5.7-不可估计)，伊匹单抗治疗后(n = 12)的SRS总生存期为10.4个月(95% CI: 1.9-不可估计)。总体而言，未见意外毒性:11%的患者出现3级中枢神经系统毒性，7%发生放射性坏死。结论:伊匹单抗治疗黑色素瘤脑转移患者SRS耐受性良好。在伊匹单抗治疗之前或期间接受SRS治疗的患者可能会提高生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.